A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Financial Summary
| Share Statistics | HYPMY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,818.1 | $618.0 | 58% |
|
| Shares Out (Mil) | 135.2 | 44.8 | 69% |
|
| Institutional Ownership | 49.4% | 85.3% | 24% |
|
| Float (Mil) | 305.7 | 47.4 | 80% |
|
| Beta | 0.11 | 0.70 | 9% |
|
| Avg Daily Volume (000s) | 13 | 390 | 18% |
|
| Price Change (52-week) |
0.3% | 68.6% | 45% |
|
| Growth | HYPMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.2% | 6.7% | 66% |
|
| Net Income (5yr) | (2.7%) | (1.6%) | 36% |
|
| EPS (5yr) | (2.7%) | 14.9% | 28 |
|
| Dividends (5yr) | (1.2%) | 0.0% | 61% |
|
| Cash Flow (5yr) | (15.3%) | (14.9%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | HYPMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,702 | $291 | 58% |
|
| Net Income (TTM) (Mil) | $337 | ($11) | 74% |
|
| EPS (TTM) | $0.518 | ($0.700) | 54% |
|
| Operating Cash Flow (TTM) (Mil) | $560 | ($6) | 73% |
|
| Net Cash Flow (TTM) (Mil) | $70 | $5 | 73% |
|
| Long-Term Debt (Q1) (Mil) | $1,412 | $6 | 70% |
|
| Enterprise Value (Q1) (Mil) | $3,995 | $450 | 59% |
|
| Valuation | HYPMY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | HYPMY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.2% | 67.0% | 74% |
|
| Net Margin | 19.8% | (2.3%) | 78% |
|
| ROA | 7.2% | (22.4%) | 80% |
|
| ROE | 13.5% | (20.2%) | 67% |
|
| Liabilities to Assets | 43.1% | 32.2% | 34% |
|
| F-Score | na | 3 | na |
|
Hypera S.A. did not pass any screens on 8/20/2026.
